Navigation Links
Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target

er in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 23,600 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit http://novonordisk.com.

References:

1. Seino Y, Kaku K, Nishijima K, et al. "Once Daily Dosing of the long acting GLP-1 analogue Liraglutide Significantly Improves Glycaemic Control by Reducing both Fasting and Post-Prandial Glucose Levels In Japanese Subjects With Type 2 Diabetes." Poster presented (abstract # 0520-P) at the 67th Scientific Sessions of the American Diabetes Association, Chicago, IL, June 23-26 2007.

2. Vilsboell T, Brock B, Perrild H, et al. 14 weeks of liraglutide therapy in subjects with T2DM significantly improves 1st phase insulin secretion and maximal beta-cell secretory capacity. Late-breaking oral presentation (abstract 750195) at: 66th annual meeting of the American Diabetes Association, Washington, DC, June 9-13, 2006.

3. Vilsboell T, Zdravkovic M, Le-Thi T, et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with type 2 diabetes. Oral presentation (abstract # 115-OR) at: 66th annual meeting of the American Diabetes Association, Washington, DC, June 9-13, 2006.'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:9/30/2014)... 2014 This study provides an analysis ... solutions including nuclear imaging informatics, PET imaging informatics, ... assesses the size of the market based on ... projects future growth based on the current drivers ... place in the broader markets for imaging equipment, ...
(Date:9/30/2014)... -- Decision Resources Group finds that the Asia Pacific ... China , India , Japan ... 2023. Dental implant procedure volumes will grow as physicians are increasingly ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... , Sept. 30, 2014 A study ... (OCT), offered a new look at the composition of ... how physicians understand and treat the disease, a leading ... at Baptist Health Lexington between September 2010 and May ... the Journal of the American College of Cardiology ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... Puma Biotechnology, Inc., a development stage biopharmaceutical ... license the worldwide commercial rights to neratinib, a ... transduction through the epidermal growth factor receptors, ErbB1 ... is being studied in the neoadjuvant, adjuvant and ...
... Corp. (OTCQB: CYCA), leading the way to cost effective ... Erik Stephansen to President of its eHealth division.  Mr. ... part of the company,s recent launch of their CyttaConnect™ ... network and its partners, FDA approved Bluetooth medical devices. ...
Cached Medicine Technology:Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 2Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 3Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 4Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 5New Leader for CyttaConnect™ Medical Monitoring eHealth Division 2New Leader for CyttaConnect™ Medical Monitoring eHealth Division 3
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
(Date:10/1/2014)... WASHINGTON, D.C. and ATLANTA (PRWEB) October 01, ... and information security executive networking and relationship-marketing ... the 2014 Information Security Executive® and Project ... Executives include top-ranking decision makers representing organizations ... and academics. Projects include large-scale technology endeavors ...
(Date:10/1/2014)... Between 23 million and 50 million people suffer ... from the National Institutes of Health (NIH) and the ... them have something else in common: They have a ... Gluten Free Therapeutics, makers of CeliVites nutritional supplements, ... publishing a series of blog posts aimed at educating ...
(Date:10/1/2014)... Scientists at the University of Western Australia say ... proteins has the power to knock out mesothelioma in ... new study on their website. Click here to ... UWA School of Pathology and Laboratory Medicine administered anti-CD25, ... with promising results. , “A timed triple immunotherapy ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 ... will speak to a group of dental specialists who ... the northern Spain city of Oviedo. Dr. Reshad of ... and lecturer with clients on two continents, will give ... and aesthetic full mouth reconstruction. , “These specialists want ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4
... cooking utensils may damage the environment, a new study ... of chemicals known as fluorinated polymers whose non-stick properties ... ,However, when heated, these polymers can emit ... toxic to plants and does not break down in ...
... new bacterial genome sequence suggests a route to new ... evade antibiotics, even minor infections can become a major ... to tackle resistant bacteria.// ,Antibiotic resistance is a ... antibiotics come from the soil bacteria Streptomyces , including ...
... report in The Journal of the American Medical Association. ... levels with a diet supplement of folic acid alone ... University of California at San Francisco and colleagues used ... cost effectiveness of lowering levels of homocystine through grains ...
... brain can grow new blood vessels after a minor stroke, which ... tries to heal itself after a stroke. We know that people ... cases. Now a study in laboratory rats reveals that the blood ... ,Researchers at the Harvard University School of Medicine in the US ...
... nitric oxide, a hormone involved in blood pressure control ... left untreated, it does not stay at one elevated ... to the researchers at the University of Texas, this ... oxide, which helps control blood pressure by dilating blood ...
... levels in men suffering from eating disorders. Men who ... than women with the same problems, researchers say.// ... the bones, which become dangerously thin and brittle. This ... essential nutrients, particularly calcium.Low bone mineral density (BMD) can ...
Cached Medicine News:
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
... The SkanWasher 400 ... 96-well microplate washer with ... pumps. The individual pressure ... a very gentle wash ...
Lab-Reader...
Fully automatic NRTL and CE certified microplate reader....
Medicine Products: